LexaGene Closes Sale to Alpine Veterinary Hospital
June 14 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a
molecular diagnostics company, announced the Company has sold
another MiQLab™ System and the CEO will present at multiple
conferences.
LexaGene CEO and Founder, Dr. Jack Regan, states,
“Following up on last weeks’ sales news, I’m pleased to report we
have sold another MiQLab System. We will be shipping this purchased
system to Alpine Veterinary Hospital in Concord, California. Alpine
Veterinary Hospital, led by Dr. Virk, provides a wide range of
services including emergency and orthopedic surgeries in the Bay
Area of California. Dr. Virk is a passionate proponent of
antimicrobial stewardship and is committed to providing the best
animal care through diagnostics. He believes the MiQLab System
offers the best solution for his hospital. We are excited that
Alpine Veterinary Hospital sees that the future of animal care
begins with the MiQLab System. We continue to gain momentum in
veterinary health as we’ve generated multiple MiQLab sale leads
from ACVIM Forum, which we attended last week, and from the hard
work of our dedicated sales team.”
In addition, the Company is pleased to announce that Dr. Regan
will be presenting at three up-coming conferences: the first is
investor focused, the second is about advancements in
microfluidics, and the third is about bio-threat detection.
On Monday, June 14, Dr. Regan will speak at Lytham Partners
Summer 2021 Investor Conference. An audio webcast of the
presentation will be made available on LexaGene’s website. LexaGene
management will also participate in one-on-one meetings throughout
the event, which runs from June 14-16. To arrange a meeting, please
contact a Lytham Partners representative at 1x1@lythampartners.com
or register at http://www.lythampartners.com/summer2021invreg.
On Tuesday, June 15, Dr. Jack Regan will present as part of the
‘Microfluidic Hotseat’ at the Annual Microfluids Consortium. The
consortium is hosted by the Centre for Business Innovation, a
collaboration managing a portfolio around specific areas of
business process and technology where members share information to
pursue like-minded business and innovation goals. The title of Dr.
Regan’s talk is Sample-to-Answer Pathogen Detection using
Flow-Through Sample Preparation and Customized Multiplex PCR.
Members will have the opportunity to meet microfluidics-enabled
startups, such as LexaGene, whose pathogen detection system offers
rapid molecular testing at the point of need, in multiple market
verticals. Registration is still available for those wanting to
watch the presentation.
Lastly, on Thursday, June 17, Dr. Regan will be a featured
speaker at the 28th International Biothreat and Pathogen Detection
Conference. His presentation, Rapidly Configurable Automate
Multiplexed Pathogen Detection System for Novel Threat Detection,
will focus on the ability of the MiQLab to be easily configured to
detect multiple pathogens in a single sample as a critical measure
in biosurveillance activities. Examples of MiQLab’s applications
for biothreat surveillance and diagnostics will be featured.
Registration is still available for those wanting to watch the
presentation. LexaGene anticipates issuing a news release on the
day of the conference to disclose any data to be presented.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
For inquiries: 800.215.1824 | ir@lexagene.com or
info@lexagene.com
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024